Contributions of HIV to non-hodgkin lymphoma mortality trends in the United States

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 9, 2016, Pages 1289-1296

  Howlader, Nadia ^a,b   Shiels, Meredith S ^a   Mariotto, Angela B ^a   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLACK PERSON; BURKITT LYMPHOMA; CANCER MORTALITY; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CAUSE OF DEATH; DEMOGRAPHY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SURVIVAL TIME; UNITED STATES; YOUNG ADULT; AGED; B CELL LYMPHOMA; DIFFUSE LARGE B CELL LYMPHOMA; EPIDEMIOLOGY; INCIDENCE; MORTALITY; RISK FACTOR; TRENDS; VIROLOGY;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKITT LYMPHOMA; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MORTALITY; RISK FACTORS; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 84986188621     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0273     Document Type: Article

References (39)

1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-62.
2. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187-94.
3. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-54.
4. Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated Cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 2015;33:2376-83.
5. Simard EP, Pfeiffer RM, Engels EA. Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods. AIDS 2012;26:1311-8.
6. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review (CSR) 1975-2012. Available from: http://seer.cancer.gov/csr/1975-2012/.
7. Clarke CA. Changing incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among young men in San Francisco. AIDS 2001;15:1913-5.
8. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002;94:2015-23.
9. Shiels MS, Engels EA, Linet MS, Clarke CA, Li J, Hall HI, et al. The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009. Cancer Epidemiol Biomarkers Prev 2013;22:1069-78.
10. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002;94:1204-10.
11. Chu KC, Miller BA, Feuer EJ, Hankey BF. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol 1994;47:1451-61.
12. Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA. Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev 2016;25:174-9.
13. SEER Lymphoma Subtype Recodes. Available from: http://seer.cancer.gov/lymphomarecode/.
14. Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e90-8.
15. Diamond C, Taylor T, Im T, Wallace M, Saven A, Anton-Culver H. How valid is using cancer registries' data to identify acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma? Cancer Causes Control 2007;18:135-42.
16. Clarke CA, Glaser SL. Population-based surveillance of HIV-associated cancers: utility of cancer registry data. JAIDS J Acquir Immune Defic Syndr 2004;36:1083-91.
17. Shiels MS, Koritzinsky EH, Clarke CA, Suneja G, Morton LM, Engels EA. Prevalence of HIV infection among U.S. Hodgkin lymphoma cases. Cancer Epidemiol Biomarkers Prev 2014;23:274-81.
18. Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS (London, England) 2014;28:2313-8.
19. SEER Cause ofDeath Recode. Available from: http://seer.cancer.gov/codrecode/.
20. Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010;102:1584-98.
21. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101-21.
22. Surveillance, Epidemiology, and End Results (SEER) Program. SEER--Stat Database: Incidence-Based Mortality-SEER 18 Regs, November 2014 Submission (1973-2012 Varying). Katrina/Rita Population Adjustment. NCI, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission. Available from: www.seer.cancer.gov.
23. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.
24. Surveillance Research Program NCI. SEER-Stat Program. Version 8.3.2. April 2016. http://seer.cancer.gov/seerstat/.
25. Surveillance Research Program NCI. Joinpoint Regression Program. Version 4.2.0.2. June 2015. http://surveillance.cancer.gov/joinpoint/.
26. Yu B, Huang L, Tiwari RC, Feuer EJ, Johnson KA. Modelling populationbased cancer survival trends using join point models for grouped survival data. J R Stat Soc Ser A Stat Soc 2009;172:405-25.
27. Surveillance Research Program NCI. JPSurv: Methods for population-based cancer survival analysis Version: 2.0.15. https://cran.r-project.org/web/packages/JPSurv/index.html.
28. Centers for Disease Control and Prevention. HIV surveillance-United States, 1981-2008. MMWR Morb Mortal Wkly Rep 2011;60:689-93.
29. Shiels MS, Pfeiffer RM, Hall H, Li J, Goedert JJ, Morton LM, et al. Proportions of Kaposi sarcoma, selected Non-hodgkin lymphomas, and Cervical cancer in the united states occurring in persons with aids, 1980-2007. JAMA 2011;305:1450-9.
30. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 2015;107:pii: dju503.
31. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 2014;28:881-90.
32. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, et al. AIDS-related Burkitt lymphoma in the United States:what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood 2010;25:5600-4.
33. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood 2012;119:3245-55.
34. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101: 4653-9.
35. Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, et al. Changes in the influence of lymphoma-and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol 2015; 26:958-66.
36. Shiels MS, Pfeiffer RM, Besson C, Clarke CA, Morton LM, Nogueira L, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 2016 Mar 18. [Epub ahead of print].
37. Manual of the International Statistical Classification of Diseases and Related Health Problems. 10th revision. Volume 2 Instructional Manual. Second Edition. Geneva, Switzerland: World Health Organization; 2004. p. 34.
38. Suneja G, Shiels MS, Angulo R, Copeland GE, Gonsalves L, Hakenewerth AM, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol 2014;32:2344-50.
39. National Comprehensive Cancer Network. Non-Hodgkin's Lymphoma Cancer (Version 4.2014). Available from: http://www.nccn.org/about/nhl.pdf.